Spectral and Metra Biosystems to merge operations
This article was originally published in Clinica
In an attempt to add critical mass to two ailing small point-of-care diagnostics companies, Spectral Diagnostics and Metra Biosystems are to merge in a transaction which will result in annual sales of around $13 million and cash resources of more than $32 million. The transaction will end with Spectral holding 51% of the as yet unnamed new company and Metra controlling the remainder.
You may also be interested in...
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.